Kathrin Philipp-Abbrederis, Ken Herrmann, Stefan Knop, Margret Schottelius, Matthias Eiber, Katharina Lückerath, Elke Pietschmann, Stefan Habringer, Carlos Gerngroß, Katharina Franke, Martina Rudelius, Andreas Schirbel, Constantin Lapa, Kristina Schwamborn, Sabine Steidle, Elena Hartmann, Andreas Rosenwald, Saskia Kropf, Ambros J Beer, Christian Peschel, Hermann Einsele, Andreas K Buck, Markus Schwaiger, Katharina Götze, Hans-Jürgen Wester, Ulrich Keller
- CXCR4 is a G-protein-coupled receptor that mediates recruitment of blood cells toward its ligand SDF-1. In cancer, high CXCR4 expression is frequently associated with tumor dissemination andpoor prognosis. We evaluated the novel CXCR4 probe [\(^{68}\)Ga]Pentixafor for invivo mapping of CXCR4 expression density in mice xenografted with human CXCR4-positive MM cell lines and patients with advanced MM by means of positron emission tomography (PET). [\(^{68}\)Ga]Pentixafor PET provided images with excellent specificity and contrast. In 10 of 14CXCR4 is a G-protein-coupled receptor that mediates recruitment of blood cells toward its ligand SDF-1. In cancer, high CXCR4 expression is frequently associated with tumor dissemination andpoor prognosis. We evaluated the novel CXCR4 probe [\(^{68}\)Ga]Pentixafor for invivo mapping of CXCR4 expression density in mice xenografted with human CXCR4-positive MM cell lines and patients with advanced MM by means of positron emission tomography (PET). [\(^{68}\)Ga]Pentixafor PET provided images with excellent specificity and contrast. In 10 of 14 patients with advanced MM [\(^{68}\)Ga]Pentixafor PET/CT scans revealed MM manifestations, whereas only nine of 14 standard [\(^{18}\)F]fluorodeoxyglucose PET/CT scans were rated visually positive. Assessment of blood counts and standard CD34\(^{+}\) flow cytometry did not reveal significant blood count changes associated with tracer application. Based on these highly encouraging data on clinical PET imaging of CXCR4 expression in a cohort of MM patients, we conclude that [\(^{68}\)Ga]Pentixafor PET opens a broad field for clinical investigations on CXCR4 expression and for CXCR4-directed therapeutic approaches in MM and other diseases.…
MetadatenAutor(en): | Kathrin Philipp-Abbrederis, Ken Herrmann, Stefan Knop, Margret Schottelius, Matthias Eiber, Katharina Lückerath, Elke Pietschmann, Stefan Habringer, Carlos Gerngroß, Katharina Franke, Martina Rudelius, Andreas Schirbel, Constantin Lapa, Kristina Schwamborn, Sabine Steidle, Elena Hartmann, Andreas Rosenwald, Saskia Kropf, Ambros J Beer, Christian Peschel, Hermann Einsele, Andreas K Buck, Markus Schwaiger, Katharina Götze, Hans-Jürgen Wester, Ulrich Keller |
---|
URN: | urn:nbn:de:bvb:20-opus-148738 |
---|
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
---|
Institute der Universität: | Medizinische Fakultät / Klinik und Poliklinik für Nuklearmedizin |
---|
| Medizinische Fakultät / Pathologisches Institut |
---|
| Medizinische Fakultät / Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) |
---|
Sprache der Veröffentlichung: | Englisch |
---|
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | EMBO Molecular Medicine |
---|
Erscheinungsjahr: | 2015 |
---|
Band / Jahrgang: | 7 |
---|
Heft / Ausgabe: | 4 |
---|
Seitenangabe: | 477-487 |
---|
Originalveröffentlichung / Quelle: | EMBO Molecular Medicine 7(4), 477-487 (2015). DOI: 10.15252/emmm.201404698 |
---|
DOI: | https://doi.org/10.15252/emmm.201404698 |
---|
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Freie Schlagwort(e): | CXCR4; CXCR4/SDF-1; FDG PET/CT; autologous transplantation; bone disease; cancer; cells; chemokine receptor; in vivo imaging; involvement; malignancies; microenvironment; multiple myeloma; positron emission tomography; survival |
---|
Datum der Freischaltung: | 21.11.2018 |
---|
Lizenz (Deutsch): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |
---|